
StimOxyGen
Improving cancer outcomes by overcoming hypoxia.
Get premium to view all results
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
* | N/A | Grant | |
Total Funding | 000k |
Related Content
More about StimOxyGen
EditMade with AI
StimOxyGen is a proprietary and world-leading innovative approach to address the global challenge of tumour hypoxia.
Hypoxia, or lack of oxygen, is a common characteristic of solid tumours that contributes to the failure of many types of cancer treatment, particularly radiotherapy which relies on oxygen for maximum efficacy.
We can solve this longstanding major unmet clinical need by fueling tumours with oxygen to maximise therapeutic effects of radiotherapy.
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads